PMID- 33297794
OWN - NLM
STAT- MEDLINE
DCOM- 20210430
LR  - 20210430
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 62
IP  - 4
DP  - 2021 Apr
TI  - No increased bleeding events in patients with relapsed chronic lymphocytic 
      leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.
PG  - 837-845
LID - 10.1080/10428194.2020.1845339 [doi]
AB  - The advent of novel B-cell receptor pathway targeting agents like ibrutinib 
      dramatically changed management of B-cell malignancies. However, with concomitant 
      anticoagulation (AC) and antiplatelet (AP) therapy, ibrutinib is associated with 
      increased bleeding. This post hoc analysis aimed to determine the role of AC/AP 
      therapy in patients with idelalisib-treated B-cell malignancies and to establish 
      if it contributes to increased bleeding events. Data from two idelalisib trials 
      (rituximab +/- idelalisib in chronic lymphocytic leukemia [CLL] and idelalisib 
      monotherapy in indolent non-Hodgkin lymphoma [iNHL]) were analyzed. 
      Antithrombotic therapy was common (36%-63%), with comparable bleeding incidence 
      across treatment groups (14%-19%; p = 0.56). Bleeding events of grade >/=3 occurred 
      in 0.9% and 3.2% of the idelalisib-treated CLL and iNHL cohorts, respectively. 
      Our findings demonstrate no increase in bleeding events with simultaneous AC/AP 
      treatment and idelalisib use. Hemorrhagic risk is prevalent in these patients and 
      an important consideration when evaluating available treatment options. 
      ClinicalTrials.gov identifiers: NCT01539512 and NCT01282424.
FAU - Barrientos, Jacqueline C
AU  - Barrientos JC
AD  - Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
FAU - Hillmen, Peter
AU  - Hillmen P
AD  - St. James's University Hospital, Leeds, UK.
FAU - Salles, Gilles
AU  - Salles G
AD  - Hospices Civils de Lyon, University Claude Bernard, Pierre Benite, France.
FAU - Sharman, Jeff
AU  - Sharman J
AD  - Willamette Valley Cancer Institute and Research Center/US Oncology Research, 
      Springfield, OR, USA.
FAU - Stilgenbauer, Stephan
AU  - Stilgenbauer S
AD  - Department of Medicine III, University of Ulm, Ulm, Germany.
FAU - Gurtovaya, Oksana
AU  - Gurtovaya O
AD  - Gilead Sciences, Inc, Foster City, CA, USA.
FAU - Xing, Guan
AU  - Xing G
AD  - Gilead Sciences, Inc, Foster City, CA, USA.
FAU - Ruzicka, Bianca
AU  - Ruzicka B
AD  - Gilead Sciences, Inc, Foster City, CA, USA.
FAU - Bhargava, Pankaj
AU  - Bhargava P
AD  - Gilead Sciences, Inc, Foster City, CA, USA.
FAU - Ghia, Paolo
AU  - Ghia P
AD  - Universita Vita-Salute San Raffaele and IRCCS Instituto Scientifico San Raffaele, 
      Milano, Italy.
FAU - Pagel, John M
AU  - Pagel JM
AD  - Swedish Cancer Institute, Seattle, WA, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT01282424
SI  - ClinicalTrials.gov/NCT01539512
GR  - UL1 TR002384/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Purines)
RN  - 0 (Quinazolinones)
RN  - YG57I8T5M0 (idelalisib)
SB  - IM
MH  - *Antineoplastic Agents/adverse effects
MH  - Humans
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell/complications/drug therapy
MH  - *Lymphoma, Non-Hodgkin/complications/drug therapy
MH  - Purines/adverse effects
MH  - Quinazolinones/adverse effects
OTO - NOTNLM
OT  - Hemorrhage
OT  - PI3K inhibitor
OT  - anticoagulant
OT  - antiplatelet
OT  - thrombocytopenia
EDAT- 2020/12/11 06:00
MHDA- 2021/05/01 06:00
CRDT- 2020/12/10 05:34
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2021/05/01 06:00 [medline]
PHST- 2020/12/10 05:34 [entrez]
AID - 10.1080/10428194.2020.1845339 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2021 Apr;62(4):837-845. doi: 10.1080/10428194.2020.1845339. Epub 
      2020 Dec 10.